ArticleFrontiers in immunology2025
Risk of infantile atopic dermatitis in neonatal lupus erythematosus: a retrospective cohort study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Seizure phenotypes and short-term prognosis in neonatal lupus: a multicenter retrospective cohort in China.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The onset and progression of atopic dermatitis (AD) are closely linked to autoimmune status. While AD has been observed in children with neonatal lupus erythematosus (NLE), its relationship with perinatal factors remains unclear. This study aimed to identify early-life risk factors for the development of AD in children with NLE within their first two years of life. Methods: We conducted a multicenter, retrospective cohort study using electronic medical records and follow-up data from patients in the NLE cohort. Children were categorized into AD and non-AD groups based on whether they developed AD by age two. Univariate and multivariate analyses were performed to compare general and clinical data between the two groups. Results: AD incidence in NLE patients was 27.27 (21/77). Compared to the non-AD group, the AD group had significantly lower use of oral probiotics and intravenous gamma globulin, but higher rates of small-for-gestational-age (SGA) status, hypocomplementemia, thrombocytopenia, anti-SSA, anti-SSB, double antibody (anti-SSA, anti-SSB) positivity, antibiotic use, and systemic glucocorticoid (GC) treatment. Logistic regression analysis revealed that oral probiotics were a protective factor against AD, while double antibody positivity and systemic GC were risk factors. Conclusion: In children with NLE, oral probiotics were associated with a reduced risk of AD, while double antibody positivity and systemic GC administration significantly increased the risk of AD within the first two years of life. However, the limited sample size in this study warrants further findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.